SLDHSerum Lactate Dehydrogenase (isoenzyme)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Interestingly, in our study, we found that the gastric cancer patients with normal but relative high SLDH levels (158.0-245.0 U/L) had a poor OS and DFS than patients with relative low SLDH levels (<157.0 U/L).
In conclusion, our results suggest that high SLDH level could be an independent poor prognostic biomarker for gastric cancer patients.
TABLE 1: Clinicopathological correlations of SLDH in gastric cancer.
High serum lactate dehydrogenase (SLDH) levels have been reported as a poor prognostic indicator in nonsmall-cell lung cancer, malignant lymphoma, pancreatic carcinoma, and colorectal cancer [11-14].
However, little is known about the association of SLDH levels with gastric cancer.
Patients were excluded from the study if they had a medical history of the same or another type of cancer previously, if they had any of the other conditions in which SLDH levels are increased, or if hemolysis was detected in their blood specimens.
SLDH levels were determined before surgical resection using a Hitachi Automatic Analyzer 7600-020 (Hitachi High-Technologies, Tokyo, Japan) with standard biochemical assays that were recommended by International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
characteristics of patients and their correlations with SLDH levels are provided in Tables 1 and 2.
As shown in Table 1, SLDH levels were closely associated with the pathological (p) T stage (P = 0.011), metastasis (P = 0.012), pTNM stage (P = 0.001), and recurrence (P = 0.012).
Moreover, we found a significant difference in the mean [+ or -] standard deviation (SD) SLDH levels among Borrmann type (P = 0.027), pT stage (P = 0.004), lymph node metastasis (P = 0.027), metastasis (P < 0.001), pTNM stage (P = 0.006), or recurrence (P = 0.002) (Table 2).